- Home
- NSIT vs TVTX Comparison
NSIT vs TVTX Comparison
Compare NSIT & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSIT | TVTX |
|---|---|---|
| Founded | 1988 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | NSIT | TVTX |
|---|---|---|
| Price | $85.65 | $34.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 15 |
| Target Price | ★ $128.33 | $37.21 |
| AVG Volume (30 Days) | 439.4K | ★ 1.6M |
| Earning Date | 10-30-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.21 | N/A |
| Revenue | ★ $8,271,548,000.00 | $435,826,000.00 |
| Revenue This Year | N/A | $120.36 |
| Revenue Next Year | $2.57 | $37.33 |
| P/E Ratio | $20.43 | ★ N/A |
| Revenue Growth | N/A | ★ 114.22 |
| 52 Week Low | $81.59 | $12.91 |
| 52 Week High | $181.92 | $37.50 |
Technical Indicators
Market Signals| Indicator | NSIT | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.42 | 56.76 |
| Support Level | $85.10 | $33.45 |
| Resistance Level | $90.38 | $35.64 |
| Average True Range (ATR) | 2.81 | 1.51 |
| MACD | 0.91 | -0.40 |
| Stochastic Oscillator | 42.78 | 39.01 |
Price Performance
Historical ComparisonAbout NSIT Insight Enterprises Inc.
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, governments, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital innovation, cloud/data center transformation, connected workforce, and supply chain optimization solutions and services.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.